Forbes Contributor, Elaine Schattner, writes about several pieces of research that were presented at the recent Annual Meeting of the American Association for Cancer Research.  A physician herself, Schattner lays out the evidence that the drug olaparib has unexpected anti-tumor activity in ovarian and prostate cancers.  SU2C was proud to support the studies presented by Ursula Matulonis, MD, of Dana-Farber Cancer Institute and Joaquin Mateo, MD, of the Institute for Cancer Research in the U.K.

In research supported in part by Stand Up To Cancer, scientists in the Netherlands have created a model using living cells that will help researchers study the processes involved in the development of colon cancer.  The model will also help discover which drugs will work against cancerous cells. 

Developed in the laboratory of Hans Clevers, MD, PhD, professor at the Hubrecht Institute in Utrecht, the model utilizes organoids, which are made from cultured human tissues. SU2C and the Dutch Cancer Society launched a Dream Team headed by Clevers along with Johannes Bos, PhD, chairman of the department of molecular cancer research at University Medical Center Utrecht, to support the organoid work in November 2013. The SU2C Dream Team grants are administered by SU2C’s Scientific Partner, the American Association for Cancer Research (AACR).

There’s a revolution taking place in emergency medical services, and for many, it could be life changing.

No exalted individual, no victory celebration, no Marie Curie or Jonas Salk, who in 1955, after he created the first polio vaccine, was asked, So what’s next? Cancer? — as if a doctor finished with one disease could simply shift his attention to another, like a chef turning from the soup to the entrée.